-
on drug development, uncovering basic mechanisms, and identifying novel therapeutic targets in leukemogenesis and solid tumors. Specifically, we study genetic and epigenetic biomarkers with prognostic value
-
are looking for a highly motivated candidate with a PhD and/or MD degree interested in combining novel rational and combinatorial synthetic biology approaches with computational methods to develop strategies
-
/surgeons to plan, design, and execute computational analyses. Advance the integration of multi-omics and clinical datasets to uncover mechanisms of tumor evolution, therapeutic resistance, and potential
-
discovery approaches and biochemical assays to target key proteins. This funded position is for a postdoctoral trainee interested in aiding the development of novel therapeutics for treating cancer
-
) development of small molecule drugs and PROTAC-drug conjugates. The Li group conducts the most forefront science and is highly productive with publications in high-impact journals in the past five years, Nature
-
priority. For more information about Dr. Vu Ngo’s research, please visit here . As a successful candidate, you will: Plan, design, and execute experiments independently and in collaboration with lab members
-
pioneering the development of neural stem cell (NSC) and extracellular vesicle (EV)-based therapies for neurodegenerative conditions, including traumatic brain injury (TBI), chemotherapy-related cognitive
-
are working on this may be the perfect opportunity: 1. Development of cell-free DNA (mutation and methylation), RNA, and exosomal-based liquid assays for early cancer detection, prognosis, and predictive
-
of Hope. This role offers an exciting opportunity to investigate immune checkpoint signaling within the tumor microenvironment and contribute to the development of novel anticancer therapies
-
Epigenetics, Epigenetics Regulation, Cancer Metabolism, Immunology, Drug Discovery, Development, and Structural Biology, with an emphasis on RNA epigenetics/epitranscriptomics (RNA modifications) and RNA-based